The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Inflammatory Bowel Disease Treatment Market Expected To Change From 2026 To 2030?
The inflammatory bowel disease treatment market size has experienced significant expansion in recent years. This market is expected to grow from $27.19 billion in 2025 to $29.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. Historically, the growth can be attributed to factors such as the increasing prevalence of ulcerative colitis and Crohn’s disease, greater awareness of IBD treatment options, the expansion of hospital and retail pharmacy networks, the availability of generic aminosalicylates, and the early adoption of biologics in developed regions.
The market for inflammatory bowel disease treatments is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $43.36 billion, demonstrating a compound annual growth rate (CAGR) of 9.8%. This projected growth is driven by several factors, including heightened investment in precision medicine, the creation of innovative anti-inflammatory treatments, the incorporation of digital health platforms for monitoring patients, the rising adoption of biologics and biosimilars, and the broader availability of IBD treatment in developing economies. Key trends expected during this period involve the evolution of personalized IBD therapies, an increased reliance on biologics in treatment protocols, the emergence of minimally invasive drug delivery systems, a stronger emphasis on patient adherence initiatives, and the expansion of specialty pharmacies catering to IBD patients.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
What Key Factors Are Shaping The Inflammatory Bowel Disease Treatment Market Landscape?
The increasing occurrence of Crohn’s disease and ulcerative colitis is significantly driving the inflammatory bowel disease treatment market. Crohn’s disease and ulcerative colitis are forms of inflammatory bowel diseases (IBD) that cause inflammation and ulcers (sores) in the digestive tract. The escalating instances of Crohn’s disease and ulcerative colitis are anticipated to boost demand for inflammatory bowel disease treatments, as these therapies are widely employed to alleviate bowel inflammation and reduce and prevent medical complications. For instance, in November 2024, according to the Crohn’s & Colitis Foundation, a US-based Non-profit organization, approximately 100,429 children and adolescents in the United States under 20 years old are affected by IBD, encompassing both Crohn’s disease and ulcerative colitis. Within this pediatric population, Crohn’s disease is more common, with a prevalence of 71 per 100,000, compared to 44 per 100,000 for ulcerative colitis. Hence, the rising prevalence of Crohn’s disease and ulcerative colitis is expected to drive the inflammatory bowel disease treatment market growth.
What Segment Categories Shape The Inflammatory Bowel Disease Treatment Market Segment Landscape?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
Which Trends Are Impacting The Progress Of The Inflammatory Bowel Disease Treatment Market?
Leading companies in the inflammatory bowel disease treatment market are developing innovative products, such as therapies for moderate to severe active ulcerative colitis, to reach broader customer bases, increase sales, and boost revenue. Treatments for moderate to severe active ulcerative colitis typically involve medications and, at times, surgical interventions. For instance, in October 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz). Available in both infusion (300 mg/15 mL) and injection (100 mg/mL) forms, Omvoh stands as the first and only interleukin-23p19 (IL-23p19) antagonist specifically designed to treat adults with moderately to severely active ulcerative colitis (UC). This medication is precisely formulated to target the p19 subunit of IL-23, thereby effectively blocking the IL-23 pathway, which is known to cause the inflammation that significantly contributes to the development of UC. The Omvoh treatment regimen commences with three 300-mg IV infusions, administered once a week every four weeks, before transitioning to a maintenance phase that includes two 100-mg subcutaneous self-injections every four weeks.
Who Are The Companies Operating Across The Inflammatory Bowel Disease Treatment Market Value Chain?
Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.
Get The Full Inflammatory Bowel Disease Treatment Market Report:
Which Region Leads The Inflammatory Bowel Disease Treatment Market In Terms Of Market Share?
North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Inflammatory Bowel Disease Treatment Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2026, By The Business Research Company
Inflammatory Bowel Disease Treatment Market Report 2026
Crohns Disease Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report
Rare Inflammatory Disease Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model